Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 Transcripts.
Petiti J, Lo Iacono M, Dragani M, Pironi L, Fantino C, Rapanotti MC, Quarantelli F, Izzo B, Divona M, Rege-Cambrin G, Saglio G, Gottardi EM, Cilloni D, Fava C. Petiti J, et al. Among authors: izzo b. J Clin Med. 2020 May 13;9(5):1457. doi: 10.3390/jcm9051457. J Clin Med. 2020. PMID: 32414125 Free PMC article.
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, Soverini S, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M; Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia. Rosti G, et al. Among authors: izzo b. Blood. 2004 Mar 15;103(6):2284-90. doi: 10.1182/blood-2003-07-2575. Epub 2003 Nov 26. Blood. 2004. PMID: 14645009 Free article. Clinical Trial.
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia. Baccarani M, et al. Among authors: izzo b. Blood. 2004 Dec 15;104(13):4245-51. doi: 10.1182/blood-2004-03-0826. Epub 2004 Aug 19. Blood. 2004. PMID: 15319292 Free article. Clinical Trial.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M. Soverini S, et al. Among authors: izzo b. J Clin Oncol. 2005 Jun 20;23(18):4100-9. doi: 10.1200/JCO.2005.05.531. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867198 Clinical Trial.
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Iacobucci I, et al. Among authors: izzo b. Clin Cancer Res. 2006 May 15;12(10):3037-42. doi: 10.1158/1078-0432.CCR-05-2574. Clin Cancer Res. 2006. PMID: 16707599 Clinical Trial.
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, Iacobucci I, Amabile M, Abruzzese E, Orlandi E, Radaelli F, Ciccone F, Tiribelli M, di Lorenzo R, Caracciolo C, Izzo B, Pane F, Saglio G, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Soverini S, et al. Among authors: izzo b. Clin Cancer Res. 2006 Dec 15;12(24):7374-9. doi: 10.1158/1078-0432.CCR-06-1516. Clin Cancer Res. 2006. PMID: 17189410
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Alimena G, Breccia M, Luciano L, Quarantelli F, Diverio D, Izzo B, De Angelis B, Mancini M, Latagliata R, Carmosino I, Nanni M, Picardi M, Rotoli B, Mandelli F, Pane F. Alimena G, et al. Among authors: izzo b. Leuk Res. 2008 Feb;32(2):255-61. doi: 10.1016/j.leukres.2007.06.008. Epub 2007 Aug 10. Leuk Res. 2008. PMID: 17692911 Clinical Trial.
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia.
Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G; Acute Leukemia Working Party of the GIMEMA group. Lo-Coco F, et al. Among authors: izzo b. Haematologica. 2008 Jul;93(7):1017-24. doi: 10.3324/haematol.12004. Epub 2008 May 27. Haematologica. 2008. PMID: 18508799 Free article. Clinical Trial.
Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D. Cilloni D, et al. Among authors: izzo b. J Clin Oncol. 2009 Nov 1;27(31):5195-201. doi: 10.1200/JCO.2009.22.4865. Epub 2009 Sep 14. J Clin Oncol. 2009. PMID: 19752335
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.
Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A. Cross NC, et al. Among authors: izzo b. Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5. Leukemia. 2015. PMID: 25652737 Free PMC article. Review.
49 results